Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure metrics:
- Shares Purchased: 780,000 Ordinary Shares on August 8, 2013.
- Price Range: Highest price paid was 1,680.25 pence per share; lowest was 1,651.50 pence per share.
- Treasury Holdings (Settled): 506,049,412 shares (9.35% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,130,412 shares (10.36% of total voting rights).
- Shares in Issue: 4,906,627,610 shares (excluding treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 780,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.36% when including unsettled purchases. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Conduct Authority's Disclosure and Transparency Rules. No specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total number of shares held in treasury (506,049,412 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.36% held in treasury including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (range 1,651.50 to 1,680.25 pence) against market trading data for August 8, 2013.
- Note that this filing does not contain operational or financial performance metrics; refer to Form 20-F or interim reports for those details.